2017
Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173).
Wesolowski R, Lustberg M, Reinbolt R, VanDeusen J, Sardesai S, Williams N, Noonan A, Dewani S, Poi M, Wilson D, Grever M, Stephens J, Puhalla S, Mathew A, Carson W, Ramaswamy B. Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173). Journal Of Clinical Oncology 2017, 35: tps1127-tps1127. DOI: 10.1200/jco.2017.35.15_suppl.tps1127.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerDay 1Hormone receptor-positive breast cancerReceptor-positive breast cancerPhase Ib studyPhase II doseProgression-free survivalPositive breast cancerOverall response rateHeat shock protein 90 inhibitorNegative breast cancerCycle 1Shock protein 90 inhibitorsPoor outcomeStandard doseAndrogen receptorHsp90 client proteinsHeat shock protein 90Ib studyResponse durationToxicity profilePaclitaxel resistanceClient proteinsDay 7
2013
NCI 8609: Interim fluoro-3’-deoxythymidine (FLT) PET imaging findings from the phase I trial of PARP inhibitor veliparib (V) and carboplatin (C) in advanced breast cancer.
Ramaswamy B, Zhang J, Hall N, Schregel K, Lustberg M, Wesolowski R, Mrozek E, Layman R, Olson E, Ottman S, Camp A, Chalmers J, Geyer S, Villalona-Calero M, Shapiro C, Grever M, Knopp M. NCI 8609: Interim fluoro-3’-deoxythymidine (FLT) PET imaging findings from the phase I trial of PARP inhibitor veliparib (V) and carboplatin (C) in advanced breast cancer. Journal Of Clinical Oncology 2013, 31: 1023-1023. DOI: 10.1200/jco.2013.31.15_suppl.1023.Peer-Reviewed Original ResearchPET/CTFLT PET/CTAdvanced breast cancerPhase I trialFLT uptakeDay 7I trialBreast cancerPARP inhibitorsFDG PET/CTFLT PET uptakeFLT-PET imagingPARP inhibitor veliparibUptake of FLTCycle 3Dose-escalation designEligible ptsDose scheduleEscalation designFLT-PETFDG uptakeTrial protocolTherapy responseBlinded fashionImaging marker